EMA Authorised: Jevtana (cabazitaxel) — Sanofi Winthrop Industrie

View source ↗

Summary

The European Medicines Agency authorised Jevtana (cabazitaxel) for prostate cancer, with Sanofi Winthrop Industrie as the marketing authorization holder (Decisi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Sanofi Winthrop Industrie. Decision date: 30/09/2025